Background-There are substantial amounts of cytoplasmic heart-type fattyacid-binding protein (FABP) (15 kDa) in myocardial tissue. The rapid release of FABP into plasma during ischaemia indicates the possibility of using this protein as a biochemical marker for ischaemic myocardial miury. Objective-To study the completeness of the release of FABP from damaged tissue in patients with acute myocardial infarction (AMI) and the suitability of serial plasma FABP concentrations for estimation of myocardial infarct size. Methods-Immunochemically assayed FABP and enzymatically assayed creatine kinase isoenzyme MB (CK-MB) and a-hydroxybutyrate dehydrogenase (HBDH) were determined serially in plasma samples from 49 patients with AMI who had been treated with thrombolytic agents within six hours after the onset of AMI. Previously validated circulatory models and a value of 2*6 h-' for the fractional clearance rate of FABP from plasma were used to calculate cumulative protein release into plasma. Results-Release of FABP was completed earlier (24-36 h) after AMI than that of CK-MB (50-70 h) and that of HBDH (> 70 h). However, infarct size estimated from the cumulative release of the proteins and expressed as gram equivalents of healthy myocardium per litre of plasma yielded a comparable value of 4-6 for both FABP and the two enzymes. Conclusion-The data indicate that FABP released from the heart after AMI is quantitatively recovered in plasma and that FABP is a useful biochemical plasma marker for the estimation of myocardial infarct size in humans. (Br HeartJ' 1994;71:135-140 
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Background-There are substantial amounts of cytoplasmic heart-type fattyacid-binding protein (FABP) (15 kDa) in myocardial tissue. The rapid release of FABP into plasma during ischaemia indicates the possibility of using this protein as a biochemical marker for ischaemic myocardial miury. Objective-To study the completeness of the release of FABP from damaged tissue in patients with acute myocardial infarction (AMI) and the suitability of serial plasma FABP concentrations for estimation of myocardial infarct size. Methods-Immunochemically assayed FABP and enzymatically assayed creatine kinase isoenzyme MB (CK-MB) and a-hydroxybutyrate dehydrogenase (HBDH) were determined serially in plasma samples from 49 patients with AMI who had been treated with thrombolytic agents within six hours after the onset of AMI. Previously validated circulatory models and a value of 2*6 h-' for the fractional clearance rate of FABP from plasma were used to calculate cumulative protein release into plasma. Results-Release of FABP was completed earlier (24-36 h) after AMI than that of CK-MB (50-70 h) and that of HBDH (> 70 h). However, infarct size estimated from the cumulative release of the proteins and expressed as gram equivalents of healthy myocardium per litre of plasma yielded a comparable value of 4-6 for both FABP and the two enzymes. Conclusion-The data indicate that FABP released from the heart after AMI is quantitatively recovered in plasma and that FABP is a useful biochemical plasma marker for the estimation of myocardial infarct size in humans. (Br HeartJ' 1994; 71:135-140) Acute myocardial infarction (AMI) in humans is usually assessed or excluded by the measurement in plasma of the activities of cardiac enzymes, such as creatine kinase isoenzyme MB (CK-MB) and a-hydroxybutyrate dehydrogenase (HBDH)1 2 or of the concentrations of cardiac proteins such as myoglobin3 4 and tropinin T.5 6 Because Myoglobin appears in substantial quantities in plasma within [2] [3] h of the onset of AMI, whereas other proteins take at least four hours, it has been suggested that myoglobin may be a biochemical marker that is especially suitable for the early assessment of AMI,78 and may also allow reperfusion to be distinguished from persistent occlusion after thrombolytic therapy.910 In addition, both cardiac enzymes and myoglobin released from the heart after AMI are completely recovered in plasma.1' 12 Hence the cumulative release of each of these markers can be used to estimate infarct size in gram equivalents of healthy myocardium per litre of plasma.
Recently, another cardiac protein, hearttype fatty-acid-binding protein (FABP), has been proposed as an early plasma marker for AMI." '-5 with phosphate buffered saline (pH 7-4) containing 0-1% bovine serum albumin and 0-05% Tween-20. The detection limit of the assay was 0 5 ,ug/l. The recovery (mean (SD)) of purified human heart FABP added in various quantities to control human plasma was 94 (12)% (n = 11) and the interassay coefficient of variation was 6-5%.
The activities of creatine kinase isoenzyme MB (CK-MB) and HBDH were measured spectrophotometrically at 25°C in a centrifugal analyser ( 19 ,ig/l for FABP, 10 U/l for CK-MB, and 160 U/l for HBDH.
CALCULATION OF CUMULATIVE PROTEIN RELEASE
Cumulative release of cardiac proteins from the onset of AMI (t = 0) up to time t, Q(t), was calculated for a two-compartment model2' as follows:
where the three terms are the actual protein concentration (or enzyme activity) in plasma, the extravascular concentration, and the amount of protein eliminated from plasma, respectively, each expressed per litre of plasma. TER, ERR, and FCR are the fractional rate constants for transcapillary escape, extravascular return, and catabolism (elimination) of protein, respectively. For CK-MB the values used were: TER = 0-014 h-', ERR = 0-018 h-', and FCR = 0 34 h-'.' 21 For HBDH the values for TER and ERR were equal to those of CK-MB, whereas FCRwas 0-015 h-'. 2' Calculation of the cumulative release of FABP was hampered by the fact that its fractional clearance rate is not known. However, turnover studies in humans of other small proteins such as myoglobin (17'2 kDa),222' lysozyme (14 kDa)24 and retinol binding protein (21 kDa)25 all showed elimination from plasma predominantly by rapid renal clearance with a half life of 10-20 min. Hence the cumulative release of myoglobin into plasma after AMI was calculated in a onecompartment (that is plasma volume) model'2 26 where the second term in the above formula was left out, so that the cumulative protein release equals the integrated plasma curve, multiplied by FCR. Because the mean half life of myoglobin in AMI patients is 16 min23 the FCR amounts to (ln 2)/(tI,2) = 2-6 h-'. This approach was validated in a separate set of 10 patients with clinically confirmed AMI in whom plasma samples were taken every hour (fig 1) . The ratio of the plasma concentrations of myoglobin and FABP remained constant throughout the period that plasma values were raised. The mean plasma myoglobin: FABP ratio differed less than 16% from the plasma reference ratio of 591. In addition a one-compartment model for circulating FABP was validated in dogs. 27 For each patient measured plasma FABP concentrations and enzyme activities were corrected by subtraction of the normal steadystate values. For this we used the respective plasma reference values (give above) or the concentration or activity measured in the first plasma sample taken from the patient when this value was lower than the reference value. Time after first onset of AMI (h) 15 Figure Q14A(mg/1), hourly samples analysis of differences (between groups) was performed with Student's t-test. The level of significance was set at p < 0 05.
Results
Mean plasma concentration or activities of the three proteins examined as a function of time for 49 patients ( fig 3) showed a large difference between the plasma kinetics of FABP and those of CK-MB and HBDH. The peak plasma concentration FABP was reached 5-7 (1I 4) h after AMI, whereas that of CK-MB was reached 117 (4A4) h after AMI and that of HBDH 28-2 (13-5) h after AMI (mean (SD), n = 49). Within 24 hours the plasma concentration of FABP had returned to normal, whereas CK-MB took 50-70 hours and HBDH more than 70 hours (fig 3) . In one patient a recurrent myocardial infarction developed soon (<10 h) after the initial AMI. The appearance of this recurrent infarction is reflected clearly in the plasma curve for FABP but is less apparent from the CK-MB and HBDH plasma curves (fig 4) .
The cumulative release patterns of the three proteins, expressed in gram equivalents of tissue per litre of plasma, also show a difference between FABP and CK-MB and HBDH The total quantities of CK-MB and HBDH depleted from dog heart after coronary occlusion equal the calculated release of these proteins into plasma. 32 The recovery of FABP in plasma after ischaemic myocardial injury has not yet been measured in experimental studies. In view of the stability of CK-MB and HBDH29 it is generally assumed that in humans too these cardiac proteins are quantitatively recovered in plasma after AMI. The fact that in the present study the estimate of infarct size (expressed in gram equivalents of healthy myocardium) based on cumulative release of FABP resemble estimates based on cumulative release of CK-MB or HBDH suggests that the recovery in plasma of FABP depleted from the heart is also essentially complete.
Release of FABP was completed earlier than that of the two enzymatic markers. The relative delay in the appearance of the enzymes in plasma may relate either to a slower release of enzymes from damaged myocardial cells or a slower transport from the interstitial space to the vascular space by lymph drainage and by increased transendothelial transport in the diseased tissue. There is evidence of binding of cytoplasmic creatine kinase to structural elements in heart muscle.3 However, a delay in the interstitial or transendothelial transport of enzymes appears most likely, because experimental studies with isolated rat hearts subjected to low-flow ischaemia and reperfusion showed no differences in the release pattern of various cardiac proteins.'4 Because CK-MB (80 kDa) and HBDH (130 kDa) are much larger than FABP (15-0 kDa) it is tempting to suggest that molecular size may well be a main determinant of the rate of protein transport from the interstitial space to the plasma space.
ESTIMATION OF INFARCT SIZE
Estimates of infarct size 72 h after the onset of AMI based on the various markers were not significantly different (fig 5) 
